Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=27366109
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 247.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 247.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27366109
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Subst+Abuse+Rehabil
2016 ; 7
(ä): 81-6
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Opioid-induced constipation: rationale for the role of norbuprenorphine in
buprenorphine-treated individuals
#MMPMID27366109
Webster LR
; Camilleri M
; Finn A
Subst Abuse Rehabil
2016[]; 7
(ä): 81-6
PMID27366109
show ga
Buprenorphine and buprenorphine-naloxone fixed combinations are effective for
managing patients with opioid dependence, but constipation is one of the most
common side effects. Evidence indicates that the rate of constipation is lower
when patients are switched from sublingual buprenorphine-naloxone tablets or
films to a bilayered bioerodible mucoadhesive buccal film formulation, and while
the bilayered buccal film promotes unidirectional drug flow across the buccal
mucosa, the mechanism for the reduced constipation is unclear. Pharmacokinetic
simulations indicate that chronic dosing of sublingually administered
buprenorphine may expose patients to higher concentrations of norbuprenorphine
than buprenorphine, while chronic dosing of the buccal formulation results in
higher buprenorphine concentrations than norbuprenorphine. Because
norbuprenorphine is a potent full agonist at mu-opioid receptors, the differences
in norbuprenorphine exposure may explain the observed differences in
treatment-emergent constipation between the sublingual formulation and the buccal
film formulation of buprenorphine-naloxone. To facilitate the understanding and
management of opioid-dependent patients at risk of developing opioid-induced
constipation, the clinical profiles of these formulations of buprenorphine and
buprenorphine-naloxone are summarized, and the incidence of treatment-emergent
constipation in clinical trials is reviewed. These data are used to propose a
potential role for exposure to norbuprenorphine, an active metabolite of
buprenorphine, in the pathophysiology of opioid-induced constipation.